Dear Editor,We would like to correspond on the publication ‘Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients’.
The third dosage of the BNT16b2 vaccine boosted the number of liver transplant cases who acquired a positive anti‐SARS‐CoV‐2s‐RBD antibody response, according to Toniutto et al.
We all believe that the vaccine is beneficial, and that liver transplant recipients may have a different immunological response to the immunisation than healthy people. The current study has the potential to provide evidence on vaccination response among liver transplant recipients. The findings of Toniutto et al
confirm the utility of the third dose. This is consistent with the findings of a recent pathophysiological investigation on the effect of the third dosage of COVID‐19 vaccination.
It should, however, consider the potential of a perplexing underlying issue. COVID‐19 may become asymptomatic, making a diagnosis more challenging. Being asymptomatic is fairly uncommon in general.
Before making a final conclusion, the potential of asymptomatic COVID‐19 must be considered.
Whether COVID‐19 is symptomatic or not, vaccination can establish immunity; however, silent infection can have a major impact on the immunological status evaluated.